107 related articles for article (PubMed ID: 10415805)
1. MMP inhibition by chemically modified tetracycline-3 (CMT-3) in equine pulmonary epithelial lining fluid.
Maisi P; Kiili M; Raulo SM; Pirilä E; Sorsa T
Ann N Y Acad Sci; 1999 Jun; 878():675-7. PubMed ID: 10415805
[No Abstract] [Full Text] [Related]
2. In vitro inhibition of matrix metalloproteinase activity in tracheal epithelial lining fluid from horses with recurrent airway obstruction.
Raulo SM; Sorsa T; Maisi P
Am J Vet Res; 2006 Jul; 67(7):1252-7. PubMed ID: 16817751
[TBL] [Abstract][Full Text] [Related]
3. Doxycycline and chemically modified tetracyclines inhibit gelatinase A (MMP-2) gene expression in human skin keratinocytes.
Uitto VJ; Firth JD; Nip L; Golub LM
Ann N Y Acad Sci; 1994 Sep; 732():140-51. PubMed ID: 7978787
[TBL] [Abstract][Full Text] [Related]
4. Functional sites of chemically modified tetracyclines: inhibition of the oxidative activation of human neutrophil and chicken osteoclast pro-matrix metalloproteinases.
Sorsa T; Ramamurthy NS; Vernillo AT; Zhang X; Konttinen YT; Rifkin BR; Golub LM
J Rheumatol; 1998 May; 25(5):975-82. PubMed ID: 9598901
[TBL] [Abstract][Full Text] [Related]
5. The effects of chemically modified tetracyclines (CMTs) on human keratinocyte proliferation and migration.
Mäkelä M; Sorsa T; Uitto VJ; Salo T; Teronen O; Larjava H
Adv Dent Res; 1998 Nov; 12(2):131-5. PubMed ID: 9972137
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of proteolytic, serpinolytic, and progelatinase-b activation activities of periodontopathogens by doxycycline and the non-antimicrobial chemically modified tetracycline derivatives.
Grenier D; Plamondon P; Sorsa T; Lee HM; McNamara T; Ramamurthy NS; Golub LM; Teronen O; Mayrand D
J Periodontol; 2002 Jan; 73(1):79-85. PubMed ID: 11846203
[TBL] [Abstract][Full Text] [Related]
7. Wound healing in aged normal and ovariectomized rats: effects of chemically modified doxycycline (CMT-8) on MMP expression and collagen synthesis.
Ramamurthy NS; McClain SA; Pirila E; Maisi P; Salo T; Kucine A; Sorsa T; Vishram F; Golub LM
Ann N Y Acad Sci; 1999 Jun; 878():720-3. PubMed ID: 10415818
[No Abstract] [Full Text] [Related]
8. Potential application of a chemically modified non-antimicrobial tetracycline (CMT-3) against metastatic prostate cancer.
Lokeshwar BL; Houston-Clark HL; Selzer MG; Block NL; Golub LM
Adv Dent Res; 1998 Nov; 12(2):97-102. PubMed ID: 9972130
[No Abstract] [Full Text] [Related]
9. A chemically modified nonantimicrobial tetracycline (CMT-8) inhibits gingival matrix metalloproteinases, periodontal breakdown, and extra-oral bone loss in ovariectomized rats.
Golub LM; Ramamurthy NS; Llavaneras A; Ryan ME; Lee HM; Liu Y; Bain S; Sorsa T
Ann N Y Acad Sci; 1999 Jun; 878():290-310. PubMed ID: 10415737
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of MMP synthesis by doxycycline and chemically modified tetracyclines (CMTs) in human endothelial cells.
Hanemaaijer R; Visser H; Koolwijk P; Sorsa T; Salo T; Golub LM; van Hinsbergh VW
Adv Dent Res; 1998 Nov; 12(2):114-8. PubMed ID: 9972133
[TBL] [Abstract][Full Text] [Related]
11. Chemically modified tetracyclines inhibit inducible nitric oxide synthase expression and nitric oxide production in cultured rat mesangial cells.
Trachtman H; Futterweit S; Greenwald R; Moak S; Singhal P; Franki N; Amin AR
Biochem Biophys Res Commun; 1996 Dec; 229(1):243-8. PubMed ID: 8954113
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of matrix metalloproteinase-mediated periodontal bone loss in rats: a comparison of 6 chemically modified tetracyclines.
Ramamurthy NS; Rifkin BR; Greenwald RA; Xu JW; Liu Y; Turner G; Golub LM; Vernillo AT
J Periodontol; 2002 Jul; 73(7):726-34. PubMed ID: 12146531
[TBL] [Abstract][Full Text] [Related]
13. Tetracycline-based MMP inhibitors can prevent fibroblast-mediated collagen gel contraction in vitro.
Myers SA; Wolowacz RG
Adv Dent Res; 1998 Nov; 12(2):86-93. PubMed ID: 9972128
[TBL] [Abstract][Full Text] [Related]
14. Use of tetracycline as an inhibitor of matrix metalloproteinase activity secreted by human bone-metastasizing cancer cells.
Duivenvoorden WC; Hirte HW; Singh G
Invasion Metastasis; 1997; 17(6):312-22. PubMed ID: 9949290
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinase inhibitor prevents acute lung injury after cardiopulmonary bypass.
Carney DE; Lutz CJ; Picone AL; Gatto LA; Ramamurthy NS; Golub LM; Simon SR; Searles B; Paskanik A; Snyder K; Finck C; Schiller HJ; Nieman GF
Circulation; 1999 Jul; 100(4):400-6. PubMed ID: 10421601
[TBL] [Abstract][Full Text] [Related]
16. Chemically modified tetracyclines stimulate matrix metalloproteinase-2 production by periodontal ligament cells.
Bildt MM; Snoek-Van Beurden AM; DeGroot J; Van El B; Kuijpers-Jagtman AM; Von den Hoff JW
J Periodontal Res; 2006 Oct; 41(5):463-70. PubMed ID: 16953823
[TBL] [Abstract][Full Text] [Related]
17. Chemically modified non-antimicrobial tetracyclines inhibit activity of phospholipases A2.
Pruzanski W; Stefanski E; Vadas P; McNamara TF; Ramamurthy N; Golub LM
J Rheumatol; 1998 Sep; 25(9):1807-12. PubMed ID: 9733464
[TBL] [Abstract][Full Text] [Related]
18. Development and application of a microplate assay method for the mass screening of MMP inhibitors.
Akizawa T; Uratani T; Matsukawa M; Kunimatsu A; Ito Y; Itoh M; Ohshiba Y; Yamada M; Seiki M
Ann N Y Acad Sci; 1999 Jun; 878():622-4. PubMed ID: 10415790
[No Abstract] [Full Text] [Related]
19. Inhibition of articular cartilage degradation in culture by a novel nonpeptidic matrix metalloproteinase inhibitor.
Billinghurst RC; O'Brien K; Poole AR; McIlwraith CW
Ann N Y Acad Sci; 1999 Jun; 878():594-7. PubMed ID: 10415783
[No Abstract] [Full Text] [Related]
20. Chemically modified tetracyclines act through multiple mechanisms directly on osteoclast precursors.
Holmes SG; Still K; Buttle DJ; Bishop NJ; Grabowski PS
Bone; 2004 Aug; 35(2):471-8. PubMed ID: 15268899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
